The investment bank set a 12-month price target of $2 for the company, saying its Verigene system and tests differentiate it from the competition.
The multi-analyte Zika virus assay was developed by a Luminex partner, GenArraytion, and is available now for research use only.
The company attributed the increase predominantly to a continued adoption of its infectious disease menu by US microbiology laboratories.
The platform and the assay were cleared by the US Food and Drug Administration in October and were launched in the US shortly thereafter.
The company's full-year revenues rose 5 percent, with revenue from assay sales increasing 15 percent for the year and 12 percent for the quarter.
The exchange warned the company that its stock could be delisted if it doesn't meet the $1.00 minimum required closing bid price.
Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.
The molecular diagnostics company also reported 35 new customer placements in the fourth quarter.
Agilent will pay Enzo $9 million to settle the suit, which involved a US patent issued to Enzo and describing non-porous solid supports for nucleic acids.
The firm priced each share at $.47, and plans to use the funding for general corporate purposes and working capital.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.